PRONAI SECURES $12 MILLION SERIES C FINANCING.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      The article reports on the over $12 million Series C preferred financing round secured by ProNAi Therapeutics Inc., a company which develop drugs for cancer and other genetically defined diseases. Topics discussed include the lead compound of the company called, PNT2258, the significance of the funding to expand ProNAi's research about the compound, and the insights of Mina Sooch, the chief executive officer (CEO) of ProNAi, on the funding.